All In Biotech

Free tool

FAERS Monitor: Femlyv

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218718 or its brand name (Femlyv, Ethinyl Estradiol, Norethindrone Acetate). Reports on generic versions are filed under their own applications.

Reports

8

Serious

7

88% of reports

Hospitalization

0

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • breast cancer metastatic2
  • abdominal pain1
  • abnormal behaviour1
  • breast cancer1
  • contralateral breast cancer1
  • dermatitis allergic1
  • dyspnoea1
  • endometrial hyperplasia1
  • energy increased1
  • mouth ulceration1
  • oestradiol increased1
  • palpitations1
  • postural orthostatic tachycardia syndrome1
  • pulmonary embolism1
  • restlessness1

Reports by year received

View as table
YearReports
20083
20101
20161
20211
20252

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,151 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
contralateral breast cancer112837.92041.93,193
oestradiol increased18772.61397.62,185
endometrial hyperplasia13253.1519.4811
postural orthostatic tachycardia syndrome11949.5311.4486
breast cancer metastatic2490.0147.5548
energy increased1445.571.2110
dermatitis allergic1209.133.451
mouth ulceration1124.819.930
restlessness171.811.517
abnormal behaviour166.410.616
breast cancer128.24.56
pulmonary embolism127.74.46
palpitations122.53.65
abdominal pain111.31.82
dyspnoea14.60.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.